MIRM Mirum Pharmaceuticals, Inc.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1759425 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY42.2%
TTM net income YoY-2,082.1%
TTM EPS YoY-1,622.6%
Revenue 3-yr CAGR66.7%
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin-133.6%
Net margin-134.8%
FCF margin-40.8%
EBITDA margin-129.6%
Returns
ROE-760.0%
ROA-99.8%
ROIC (approx.)—
Asset turnover0.74x
Leverage & solvency
Liabilities / assets105.3%
Debt / equity—
Current ratio2.07x
Interest coverage-78.36x
Cash quality & payout
Operating cash flow / net income0.30x
Accruals ratio-69.8%
Payout ratio—
Capex / revenue0.4%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | $521.31M | $336.89M |
| R&D expense | $186.18M | $140.63M |
| SG&A expense | $257.03M | $202.22M |
| Operating income | -$22.14M | -$87.61M |
| Interest expense | $14.39M | $14.31M |
| Pretax income | -$21.43M | -$86.91M |
| Income tax | $1.94M | $1.03M |
| Net income | -$23.36M | -$87.94M |
| EBITDA | $2.11M | -$63.98M |
| EPS (basic) | -0.47 | -1.85 |
| EPS (diluted) | -0.47 | -1.85 |
| Weighted avg. shares (diluted) | 50.20M | 47.52M |
| Balance sheet | ||
| Cash & equivalents | $296.68M | $222.50M |
| Short-term investments | $86.64M | $57.81M |
| Receivables | $123.33M | $78.29M |
| Inventory | $24.89M | $22.40M |
| Current assets | $549.68M | $392.79M |
| PP&E, net | $1.86M | $1.14M |
| Intangibles | $260.92M | $249.82M |
| Total assets | $842.81M | $670.75M |
| Current liabilities | $205.80M | $126.55M |
| Total liabilities | $528.12M | $445.11M |
| Shareholders' equity | $314.69M | $225.64M |
| Shares outstanding | 51.90M | 48.34M |
| Cash flow statement | ||
| Operating cash flow | $55.83M | $10.32M |
| Capital expenditure | $954,000 | $993,000 |
| Free cash flow | $54.87M | $9.33M |
| Investing cash flow | -$23.95M | -$90.12M |
| Financing cash flow | $40.14M | $17.70M |
| Depreciation & amortization | $24.24M | $23.63M |
| Stock-based compensation | $71.42M | $48.44M |
Free plan shows the latest 2 periods; Pro shows all 7 🔒
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.